Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
9
×
national blog main
national top stories
9
×
boston blog main
boston top stories
new york blog main
san francisco blog main
new york top stories
san francisco top stories
biotech
san diego blog main
san diego top stories
deals
detroit blog main
detroit top stories
fda
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
cancer
clinical trials
drugs
national
roche
san francisco
startups
amgen
cholesterol
crispr
eli lilly
gene therapy
genentech
indiana blog main
What
big
9
×
medicine
week
ago
bio
cas
ceo
companies
crispr
drug
make
medical
medicines
meeting
new
startup
today
year
abuzz
aces
acquire
admits
agreed
aiming
amarin
ambys
american
announced
approval
arguments
ash
available
based
billion
biosciences
biotech
biotechs
blood
bosley's
bosley’s
Language
unset
Current search:
big
×
" national top stories "
×
" life sciences "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Deeper Dive: Amarin Fish-Oil Study Gives Eager Doctors More to Ponder
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine